- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04256317
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML
September 29, 2023 updated by: Astex Pharmaceuticals, Inc.
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Study ASTX030-01 is designed to move efficiently from Phase 1 to Phase 3. Phase 1 consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose Expansion Stage (Stage B) of ASTX030.
Phase 2 is a randomized open-label crossover study to compare oral ASTX030 to subcutaneous (SC) azacitidine.
Phase 3 is a randomized open-label crossover study comparing the final oral ASTX030 dose to SC azacitidine.
The duration of the study is expected to be approximately 48 months.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
317
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: General Inquiries
- Phone Number: 925-560-0100
- Email: clinicaltrials@astx.com
Study Locations
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- John Theurer Cancer Center / Hackensack University
-
-
New York
-
Buffalo, New York, United States, 14263
- Recruiting
- Roswell Park Comprehensive Cancer Center
-
Mineola, New York, United States, 11501
- Recruiting
- New York University Langone Hospital - Long Island Site# 153
-
New York, New York, United States, 10065
- Recruiting
- Weill Cornell Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health and Science University
-
Salem, Oregon, United States, 97301
- Recruiting
- Oregon Oncology Specialists
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Recruiting
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, United States, 98109
- Recruiting
- Seattle Cancer Care Alliance
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Confirmed MDS, CMML, MDS/MPN, or AML who are candidates to receive and benefit from single agent azacitidine as follows and as applicable according to local country approvals and/or local institution standard practice:
- French-American-British myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), or MDS with intermediate-2 or high risk MDS according to the International Prognostic Scoring System (IPSS). MDS/MPN patients including CMML according to the World Health Organization (WHO) 2016 classification are also eligible if they are candidates to receive single agent azacitidine per local institution standards; or
- Previously untreated AML with 20% to 30% blasts present in bone marrow and multi-lineage dysplasia (Phase 2 and 3 only); or
- Previously untreated AML with >30% blasts present in bone marrow, who are not eligible for stem cell transplant and unfit for intensive chemotherapy induction (Phase 2 and 3 only).
- Participants with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Participants with adequate organ function defined as:
- Hepatic: Total or direct bilirubin ≤2 × upper limit of normal (ULN); aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) ≤2.5 × ULN.
- Renal: Calculated creatinine clearance >50 mL/min/1.73 m^2 by Cockcroft-Gault formula or other medically acceptable formulas.
- For participants with prior allogeneic stem cell transplant, no evidence of graft-versus-host disease (GVHD) and must be ≥2 weeks off systemic immunosuppressive therapy before start of study treatment.
- Participants with no major surgery within 2 weeks before first study treatment.
- Participants with no cytotoxic chemotherapy within 4 weeks before first study treatment.
- Able to swallow the number of tablets/capsules required for the treatment assignment within a 10-minute period and tolerate 4 hours of fasting.
- Participants with projected life expectancy of at least 12 weeks.
- Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.
Exclusion Criteria:
- Active uncontrolled gastric or duodenal ulcer.
- Poor medical risk because of other conditions such as uncontrolled systemic diseases or active uncontrolled bacterial, viral, or fungal infections.
- Life-threatening illness (e.g., uncontrolled bleeding and patients at risk for or are experiencing leukostasis [AML]), uncontrolled medical condition or organ system dysfunction, or other reasons, which, in the investigator's opinion, could compromise the participant's safety, interfere with the absorption or metabolism of oral cedazuridine + azacitidine or compromise the integrity of the study outcomes.
- Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, prostate cancer or breast cancer under control with hormone therapy, or other cancer from which the participant has been disease free for at least 2 years.
- Participants with MDS/MPN who have clinical extramedullary disease including clinically palpable hepatomegaly or splenomegaly.
- Previous treatment with more than 1 cycles of decitabine, azacitidine, or guadecitabine (Phases 2 and 3 only).
- Treated with any investigational drug or therapy within 2 weeks, or 5 half lives, whichever is longer, before the protocol-defined first dose of study treatment, or ongoing clinically significant adverse events from previous treatment with investigational drug or therapy.
- Known or suspected hypersensitivity to cedazuridine or azacitidine, or any of their excipients.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1, Stage A (Dose Escalation)
In Cycle 1 (28 days per cycle), single dose oral azacitidine will be administered, followed by subcutaneous (SC) azacitidine, ASTX030 and oral cedazuridine on a specific dosing schedule; in Cycle 2, oral ASTX030 (cedazuridine + azacitidine) will be administered
|
Tablets/Capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration
Other Names:
Tablets/Capsules for oral administration
Tablets for oral administration
|
Experimental: Phase 1, Stage B (Dose Expansion)
Oral cedazuridine + azacitidine will be administered separately at the recommended dose for expansion (RDE)
|
Tablets/Capsules for oral administration
|
Experimental: Phase 2, Sequence A
Oral ASTX030 (cedazuridine + azacitidine) will be administered in Cycle 1, followed by SC azacitidine in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
|
Tablets/Capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration
Other Names:
Tablets/Capsules for oral administration
|
Experimental: Phase 2, Sequence B
SC azacitidine will be administered in Cycle 1, followed by oral cedazuridine + azacitidine tablets/capsules in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
|
Tablets/Capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration
Other Names:
Tablets/Capsules for oral administration
|
Experimental: Phase 3, Sequence A
Participants will receive ASTX030 in Cycle 1, followed by SC azacitidine in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
|
Tablets/Capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration
Other Names:
Tablets/Capsules for oral administration
|
Experimental: Phase 3, Sequence B
Participants will receive SC azacitidine in Cycle 1 followed by ASTX030 in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
|
Tablets/Capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration
Other Names:
Tablets/Capsules for oral administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total cycle area under the curve (AUC)0-24 exposures
Time Frame: Up to 2 months
|
Ratio of azacitidine total cycle AUC0-24 exposures after oral ASTX030 over SC azacitidine
|
Up to 2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: Number of TEAEs
Time Frame: Up to 36 months
|
Number of participants with treatment-emergent adverse events (TEAEs)
|
Up to 36 months
|
Change in DNA methylation
Time Frame: Baseline in Phase 1 to the end of Cycle 2 in Phase 3 (28 days per cycle)
|
Percent long interspersed nuclear elements 1 (LINE-1) methylation change (demethylation) from baseline in Cycle 1 (Phase 1) and compared between SC azacitidine and ASTX030 in Cycles 1 and 2 (Phase 2 and 3)
|
Baseline in Phase 1 to the end of Cycle 2 in Phase 3 (28 days per cycle)
|
Best clinical response rate for participants with MDS, CMML, or MDS/myeloproliferative neoplasms (MPN)
Time Frame: Up to 36 months
|
The number of participants with a complete response (CR), marrow complete response (mCR), partial response (PR), and hematologic improvement (HI) will be evaluated using International Working Group (IWG) 2006 MDS response criteria
|
Up to 36 months
|
Best clinical response rate for participants with AML
Time Frame: Up to 36 months
|
The number of participants with CR, CRi (CR with incomplete hematologic recovery), CRh (complete response with partial hematological recovery), and PR will be evaluated using European LeukemiaNet (ELN) 2017 AML response criteria and Kantarjian et al. (2017)
|
Up to 36 months
|
AML-free survival for participants with MDS, CMML, or MDS/MPN
Time Frame: Up to 36 months
|
Number of days from the date of randomization (date of first treatment in Phase 1) to either the date of MDS, CMML, or MDS/MPN progression to AML or the date of death from any cause
|
Up to 36 months
|
Duration of response
Time Frame: Up to 36 months
|
Number of days from the date that criteria are met for response until the first date that recurrent or progressive disease is documented by the investigating physician
|
Up to 36 months
|
Overall survival
Time Frame: Up to 36 months
|
Number of days from the date the participant was randomized (date of first treatment in Phase 1) to the date of death, regardless of cause
|
Up to 36 months
|
Time to response
Time Frame: Up to 36 months
|
Number of days from the start of treatment until the participant's first day of best response
|
Up to 36 months
|
Red blood cell (RBC) transfusion independence (TI)
Time Frame: Up to 36 months
|
Number of participants with RBC TI, defined as no RBC transfusion for 56 consecutive days while maintaining hemoglobin ≥8 g/dL
|
Up to 36 months
|
Platelet transfusion independence (TI)
Time Frame: Up to 36 months
|
Number of participants with platelet TI, defined as no platelet transfusion for 56 consecutive days while maintaining platelets ≥20×10^9/L
|
Up to 36 months
|
Pharmacokinetic parameter AUC
Time Frame: Up to Day 8 in Cycle 2 (28 days per cycle)
|
Area under the curve (AUC)
|
Up to Day 8 in Cycle 2 (28 days per cycle)
|
Pharmacokinetic parameter Cmax
Time Frame: Up to Day 8 in Cycle 2 (28 days per cycle)
|
Maximum plasma concentration (Cmax)
|
Up to Day 8 in Cycle 2 (28 days per cycle)
|
Pharmacokinetic parameter Tmax
Time Frame: Up to Day 8 in Cycle 2 (28 days per cycle)
|
Time to reach maximum plasma concentration (Tmax)
|
Up to Day 8 in Cycle 2 (28 days per cycle)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 21, 2020
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
April 1, 2026
Study Registration Dates
First Submitted
January 31, 2020
First Submitted That Met QC Criteria
February 3, 2020
First Posted (Actual)
February 5, 2020
Study Record Updates
Last Update Posted (Actual)
October 2, 2023
Last Update Submitted That Met QC Criteria
September 29, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Disease Attributes
- Disease
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Precancerous Conditions
- Chronic Disease
- Syndrome
- Myelodysplastic Syndromes
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Preleukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Azacitidine
Other Study ID Numbers
- ASTX030-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
Clinical Trials on Azacitidine
-
Shandong Provincial HospitalUnknownMyelodysplastic Syndromes,Acute Myeloid LeukemiaChina
-
TJ Biopharma Co., Ltd.Recruiting
-
Peter MacCallum Cancer Centre, AustraliaGlaxoSmithKline; Celgene CorporationCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)Australia
-
Eisai Inc.TerminatedMyelodysplastic SyndromesUnited States
-
Navy General Hospital, BeijingRecruitingRefractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin LymphomaChina
-
University of BirminghamRecruitingAcute Myeloid Leukemia | MyelodysplasiaUnited Kingdom
-
Nanexa ABUppsala UniversityCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)Sweden
-
The First Affiliated Hospital of Soochow UniversityEnrolling by invitationMyelodysplastic/Myeloproliferative Neoplasms | AdultChina
-
Bristol-Myers SquibbRecruitingMyelodysplastic SyndromesUnited States, Japan, Argentina, Hong Kong, Greece, Italy, China, Australia, Spain, Austria, Denmark, Germany, Sweden, Switzerland, Canada, Czechia, Korea, Republic of, Poland, Turkey, France
-
CelgeneCompletedMyelodysplastic SyndromesUnited States